Novo Nordisk | Center for Technology Transfer & Commercialization

Proteins and peptides: Discovery and development of therapeutic proteins, peptides and antibodies, including alternative delivery of biologics e.g., oral or extended release
RNA-based therapies: Biological processes to silence and alter genes that cause or contribute to diseases. Tissue targeting technologies and innovation to improve manufacturability/scalability
Small molecules: Pre-clinical and clinical assets in core TAs, as well as development and production capabilities
Gene and cell therapies: Targeting DNA to deliver a true cure for genetic diseases. Specialised cells and technology/devices for regenerative or curative cell therapies
Emerging, novel and next-generation technologies with disruptive potential

Digital: Solutions to improve outcomes and adherence through digital therapeutics, diagnostics, monitoring, prediction of disease progression and risk management
Data: To improve patient outcomes and drug discovery through access and products in patient, clinical, non-clinical data, discovery, research, analytics and scientific data sources
Diagnostics: To identify the right patient, predict and diagnose the disease and comorbidities, monitor outcomes and treatment response through in vitro, behavioural and digital tests
Devices: Connected solutions to enable patient insight and simple to use delivery systems

Novel and/or complementary approaches to energy intake and energy expenditure regulation
Quality of weight loss and co-morbidity improvements, as well as transformational prevention approaches

Novel bypassing agents, cell and gene-therapies within rare blood and haemato-renal disorders
Rare adrenal, pituitary and growth diseases within rare endocrine disorders